Elizabeth Thompson
Nurse Practitioner · Ogden, UTNPI 1588015366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$662
- Novo Nordisk$539
- AstraZeneca$291
- Lilly USA, LLC$271
- Pfizer$174
- Amarin Pharma, Inc.$132
- plus $2K from 42 others
What the payments were for
- Food & beverage$4,171100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$125
- EVENITY$122
- Wegovy$119
How this compares
$4,171 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $163,381 |
| EliquisApixaban | 63 | $71,178 |
| TrulicityDulaglutide | 56 | $63,855 |
| MyrbetriqMirabegron | 61 | $48,736 |
| MounjaroTirzepatide | 43 | $48,201 |
| FarxigaDapagliflozin Propanediol | 52 | $43,081 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $41,956 |
| JardianceEmpagliflozin | 18 | $31,977 |
| XareltoRivaroxaban | 30 | $27,494 |
| VraylarCariprazine Hcl | 15 | $21,687 |
| RybelsusSemaglutide | 19 | $20,688 |
| JanuviaSitagliptin Phosphate | 15 | $17,330 |
| Nurtec OdtRimegepant Sulfate | 14 | $13,089 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $11,902 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $539 | $184,068187 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $271 | $112,05699 claims |
| PfizerEliquis, Nurtec Odt | $174 | $84,26777 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $291 | $58,45380 claims |
| Astellas Pharma US IncMyrbetriq | $91 | $48,73661 claims |
| Johnson & JohnsonXarelto | $126 | $27,49430 claims |
| AbbVieVraylar, Synthroid | $662 | $23,67350 claims |
| MerckJanuvia | $53 | $17,33015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $9,72316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Ogden
- Stacie EganOgden$170K
- Lynn LarsenOgden$16K
- Marinda PaskettOgden$13K
- Ryan WestbroekOgden$12K
- Aaron AdamsOgden$12K
- Austin BennionOgden$9K
- Raymond MillerOgden$6K
- Nancy ShinaOgden$4K
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.